Original ArticleNon–Small Cell Lung CancerA Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Keywords
Cited by (0)
Disclosure: Dr. Paz-Ares reports receiving honoraria (self/spouse) for scientific advice or as a speaker for Adacap, Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Incyte, Ipsen, Eli Lilly, Merck Sharp & Dohme, Merck, Novartis, PharmaMar, Pfizer, Roche, Sanofi, Servier, and Sysmex; is a board member for Genómica and Altum Sequencing; and has received grants for the institution from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and Pfizer. Dr. Vicente reports receiving honoraria (self/spouse) for scientific advice or as a speaker from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, and Roche. Dr. Robinson reports receiving funding for clinical trials from AstraZeneca, Merck, Pfizer, and Roche; and is an advisory board member for Merck. Dr. Soto Parra is an advisory board member for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, and Roche. Dr. Mazières reports receiving honoraria from AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Boehringer Ingelheim, Merck, Merck Sharp & Dohme, Pfizer, PharmaMar, Pierre Fabre, and Roche; and grants for the institution from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and Roche. Dr. Hermes reports receiving travel accommodations from Eli Lilly and PharmaMar; honoraria for lectures or scientific advice from Bristol-Myers Squibb and Pfizer; and funding for the institution from Bayer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, PharmaMar, and Roche. Dr. Cicin is an advisory board member for AstraZeneca, Boehringer Ingelheim, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp & Dohme, and Pfizer; has received personal fees for lectures from Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Quintiles, and Roche; and funding for the institution to support trial conduct from Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Parexel, Pfizer, Quintiles, and Taiho. Dr. Medgyasszay reports receiving honoraria for lectures from Merck, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Novartis; and funding on behalf of the institution to support trial conduct from Merck, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Novartis, Astellas, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Parexel, Pfizer, Quintiles, and Taiho. Dr. Rodríguez-Cid reports receiving funding on behalf of the institution during the conduct of this trial from Merck Sharp & Dohme, Bayer, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis, and Roche. Dr. Okamoto reports receiving grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Merck Sharp & Dohme Oncology, Ono Pharmaceutical, and Taiho; personal fees from Pfizer; and grants from AbbVie, Astellas Pharma, and Novartis. Dr. Ramlau reports receiving honoraria (self/spouse) as a scientific adviser or as a speaker from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Sanofi; and is a board member for AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda. Drs. Deng, Zhang, and Bas are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey. Dr. Piperdi is an employee of and owns stock in Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey. Dr. Halmos reports receiving research funding from AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Guardant Health, Merck, Mirati, Novartis, Pfizer, and Takeda; and is a consultant for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech, Guardant Health, Merck, Novartis, Pfizer, and Spectrum. Drs. Tafreshi, Lee, Vladimirov, and Cheng report receiving funding on behalf of their institutions from Merck to support study conduct.